
You are here
Consultations
We conduct public consultations as part of our broader stakeholder engagement work, including on changes to regulatory requirements or practices, reviews of business processes, standards or guidelines, and TGA fees and charges.
Filters
Status
Categories
- Advertising (2) Apply Advertising filter
- Remove Advisory bodies/Committees filter Advisory bodies/Committees (1)
- Australian Register of Therapeutic Goods (ARTG) (1) Apply Australian Register of Therapeutic Goods (ARTG) filter
- Biologicals (2) Apply Biologicals filter
- Complementary medicines (7) Apply Complementary medicines filter
- Fees/Payments (1) Apply Fees/Payments filter
- Remove Import/Export filter Import/Export (1)
- Labelling/Packaging (1) Apply Labelling/Packaging filter
- Legislation (3) Apply Legislation filter
- Remove Listed medicines filter Listed medicines (2)
- Medical devices/IVDs (55) Apply Medical devices/IVDs filter
- Remove Medical devices safety filter Medical devices safety (1)
- Medicines (2) Apply Medicines filter
- Medicines safety (1) Apply Medicines safety filter
- OTC medicines (12) Apply OTC medicines filter
- Other therapeutic goods (1) Apply Other therapeutic goods filter
- Prescription medicines (5) Apply Prescription medicines filter
- Remove Safety of medicines & medical devices filter Safety of medicines & medical devices (0)
- Scheduling (85) Apply Scheduling filter
- Sunscreens (1) Apply Sunscreens filter
- Therapeutic Goods Administration (TGA) (2) Apply Therapeutic Goods Administration (TGA) filter
- Therapeutic goods regulation (2) Apply Therapeutic goods regulation filter
- (-) Remove Advisory bodies/Committees filter Advisory bodies/Committees
- (-) Remove Safety of medicines & medical devices filter Safety of medicines & medical devices
- (-) Remove Medical devices safety filter Medical devices safety
- (-) Remove Listed medicines filter Listed medicines
- (-) Remove Import/Export filter Import/Export
Proposed changes to the Permissible Ingredients Determination: Low-negligible risk changes 2021-22
Closed on 15 September 2021
IMDRF consultation: Proposed update to document on Post-Market Clinical Follow-Up Studies
Closed on 11 December 2020
Export of therapeutic goods from Australia
Closed on 3 February 2020
Changes to permissible ingredients - Low-negligible risk
Closed on 11 October 2019